NM_000361.3:c.1483C>T

Variant summary

Our verdict is Benign. The variant received -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_000361.3(THBD):​c.1483C>T​(p.Pro495Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00137 in 1,609,724 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.00067 ( 1 hom., cov: 33)
Exomes 𝑓: 0.0014 ( 2 hom. )

Consequence

THBD
NM_000361.3 missense

Scores

4
14

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:3B:4O:1

Conservation

PhyloP100: -0.445

Publications

13 publications found
Variant links:
Genes affected
THBD (HGNC:11784): (thrombomodulin) The protein encoded by this intronless gene is an endothelial-specific type I membrane receptor that binds thrombin. This binding results in the activation of protein C, which degrades clotting factors Va and VIIIa and reduces the amount of thrombin generated. Mutations in this gene are a cause of thromboembolic disease, also known as inherited thrombophilia. [provided by RefSeq, Jul 2008]
THBD Gene-Disease associations (from GenCC):
  • atypical hemolytic-uremic syndrome with thrombomodulin anomaly
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • thrombomodulin-related bleeding disorder
    Inheritance: AR, AD, Unknown Classification: STRONG, MODERATE, SUPPORTIVE, LIMITED Submitted by: ClinGen, Orphanet, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.023445576).
BP6
Variant 20-23048022-G-A is Benign according to our data. Variant chr20-23048022-G-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 12720.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.000669 (102/152372) while in subpopulation NFE AF = 0.00129 (88/68038). AF 95% confidence interval is 0.00107. There are 1 homozygotes in GnomAd4. There are 47 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAdExome4 at 2 AR,AD,Unknown gene

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_000361.3. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
THBD
NM_000361.3
MANE Select
c.1483C>Tp.Pro495Ser
missense
Exon 1 of 1NP_000352.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
THBD
ENST00000377103.3
TSL:6 MANE Select
c.1483C>Tp.Pro495Ser
missense
Exon 1 of 1ENSP00000366307.2
ENSG00000296483
ENST00000739851.1
n.795+2797C>T
intron
N/A

Frequencies

GnomAD3 genomes
AF:
0.000670
AC:
102
AN:
152252
Hom.:
1
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000265
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000654
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00129
Gnomad OTH
AF:
0.000955
GnomAD2 exomes
AF:
0.000493
AC:
117
AN:
237468
AF XY:
0.000433
show subpopulations
Gnomad AFR exome
AF:
0.0000687
Gnomad AMR exome
AF:
0.0000297
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0000993
Gnomad NFE exome
AF:
0.00105
Gnomad OTH exome
AF:
0.000346
GnomAD4 exome
AF:
0.00144
AC:
2101
AN:
1457352
Hom.:
2
Cov.:
30
AF XY:
0.00137
AC XY:
992
AN XY:
724712
show subpopulations
African (AFR)
AF:
0.000120
AC:
4
AN:
33426
American (AMR)
AF:
0.00
AC:
0
AN:
44218
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25966
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39536
South Asian (SAS)
AF:
0.0000117
AC:
1
AN:
85786
European-Finnish (FIN)
AF:
0.000249
AC:
13
AN:
52244
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5760
European-Non Finnish (NFE)
AF:
0.00177
AC:
1967
AN:
1110272
Other (OTH)
AF:
0.00193
AC:
116
AN:
60144
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
158
316
474
632
790
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
80
160
240
320
400
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000669
AC:
102
AN:
152372
Hom.:
1
Cov.:
33
AF XY:
0.000631
AC XY:
47
AN XY:
74512
show subpopulations
African (AFR)
AF:
0.000264
AC:
11
AN:
41596
American (AMR)
AF:
0.0000653
AC:
1
AN:
15312
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5176
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4832
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10628
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00129
AC:
88
AN:
68038
Other (OTH)
AF:
0.000945
AC:
2
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.487
Heterozygous variant carriers
0
6
11
17
22
28
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00112
Hom.:
0
Bravo
AF:
0.000691
TwinsUK
AF:
0.00297
AC:
11
ALSPAC
AF:
0.00104
AC:
4
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.00140
AC:
12
ExAC
AF:
0.000446
AC:
54

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:3Benign:4Other:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:1Benign:2
Mar 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

THBD: BP4, BS1, BS2

Jan 18, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Mar 19, 2021
Mayo Clinic Laboratories, Mayo Clinic
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Atypical hemolytic-uremic syndrome Pathogenic:1Uncertain:1
Oct 13, 2021
Genome Diagnostics Laboratory, The Hospital for Sick Children
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Sep 06, 2018
Sydney Genome Diagnostics, Children's Hospital Westmead
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

This patient is heterozygous for a known pathogenic variant, c.1483C>T (p.Pro495Ser), in the THBD gene. This variant (dbSNP: rs1800578) is in the ExAC database (http://exac.broadinstitute.org) with an allele frequency of 0.10% (51/50264 alleles) in the European non-Finnish population. It has also been reported in a patient with recurrent atypical hemolytic-uremic syndrome (aHUS) with the first episode at 3 years of age. Other clinical findings were residual renal dysfunction and low serum C3 levels (Delvaeye et al 2009 N Eng J Med 361:345-57). The authors also performed in vitro functional studies which showed the mutant THBD protein did not protect against complement activation.

Thrombomodulin-related bleeding disorder Uncertain:1Benign:1
Sep 22, 2025
Genomenon, Inc, Genomenon, Inc
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:curation

THBD p.Pro495Ser (c.1483C>T) is a missense variant that changes the amino acid at residue 495 from Proline to Serine. This variant has been reported in the published literature (PMID:11986219;28844315;19625716;30487789;30674459;28752844;34970867). In silico models agree that this variant is not damaging. This variant’s allele frequency in gnomAD is greater than expected for this disorder. In conclusion, we classify THBD p.Pro495Ser (c.1483C>T) as a likely benign variant.

ISTH-SSC Genomics in Thrombosis and Hemostasis, KU Leuven, Center for Molecular and Vascular Biology
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

THBD-related disorder Benign:1
Feb 05, 2024
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).

Atypical hemolytic-uremic syndrome with thrombomodulin anomaly Other:1
Jul 23, 2009
OMIM
Significance:risk factor
Review Status:no assertion criteria provided
Collection Method:literature only

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.088
BayesDel_addAF
Benign
-0.36
T
BayesDel_noAF
Benign
-0.29
CADD
Benign
3.6
DANN
Benign
0.90
DEOGEN2
Uncertain
0.54
D
Eigen
Benign
-1.0
Eigen_PC
Benign
-1.1
FATHMM_MKL
Benign
0.13
N
LIST_S2
Benign
0.44
T
M_CAP
Benign
0.064
D
MetaRNN
Benign
0.023
T
MetaSVM
Benign
-0.94
T
MutationAssessor
Uncertain
2.3
M
PhyloP100
-0.45
PrimateAI
Benign
0.33
T
PROVEAN
Uncertain
-2.7
D
REVEL
Benign
0.28
Sift
Benign
0.15
T
Sift4G
Uncertain
0.056
T
Polyphen
0.068
B
Vest4
0.17
MVP
0.31
ClinPred
0.015
T
GERP RS
-0.88
Varity_R
0.050
gMVP
0.58
Mutation Taster
=95/5
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1800578; hg19: chr20-23028659; API